Abstract
The present invention relates to a Beclin 1-UVRAG complex structure which reveals a tightly packed coiled coil assembly with Beclin 1 and UVRAG residues complementing each other to form a stable dimeric complex. This potent physical interaction is critical for UVRAG-dependent EGFR degradation but less critical for autophagy. Targeting the Beclin 1 coiled coil domain with rationally designed stapled peptides leads to enhanced autophagy activity and EGFR degradation in non-small cell lung cancer (NSCLC) cell lines, suggesting translational value for these compounds.
Original language | English |
---|---|
Patent number | US10618939 |
IPC | A61P35/00 |
Priority date | 29/06/16 |
Filing date | 14/03/18 |
Publication status | Published - 14 Apr 2020 |